André Luiz Pinheiro de Moura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
André Luiz Pinheiro de Moura has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Matheus Oliveira Do Nascimento
Graduate Program in Pharmaceutical Sciences, Federal University of Piauí, Teresina, Brazil
4 shared publications - André Luis Menezes Carvalho
Graduate Program in Pharmaceutical Sciences, Federal University of Piauí, Teresina, Brazil
3 shared publications - Charllyton Luis Sena da Costa
Graduate Program in Pharmaceutical Sciences, Federal University of Piauí, Teresina, Brazil
2 shared publications - Danielle Costa Lopes
Graduate Program in Pharmaceutical Sciences, Federal University of Piauí, Teresina, Brazil
2 shared publications - Fernando Aécio de Amorim Carvalho
Graduate Program in Pharmaceutical Sciences, Federal University of Piauí, Teresina, Brazil
2 shared publications - Francisco Gesley de Sousa Abreu
Department of Pharmacy, Federal University of Piauí, Teresina, Brazil
2 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 127
Development and in vivo evaluation of nanostructured formulations for topical anesthesia in an orofacial pain model
- 6 October 2026
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 127
Open AccessDevelopment and in vivo evaluation of nanostructured formulations for topical anesthesia in an orofacial pain model
- Open Access
- 17 February 2026
- Published by Elsevier in SSRN Electronic Journal
Development and in Vivo Evaluation of Nanostructured Formulations for Topical Anesthesia in an Orofacial Pain Model
To develop and characterize nanostructured formulations of tetracaine and to evaluate their antinociceptive activity in an in vivo model of formalin-induced orofacial pain. Microemulsions of tetracaine (MET) and its gelled version containing 4% chitosan (MEGT) were obtained. The formulations were characterized for particle size, polydispersity index (PDI), zeta potential (ZP), mucoadhesiveness, and in vitro release. In the in vivo study, forty-two female Wistar rats were allocated into seven groups (n = 6): control, eye drops (1% tetracaine + 0.1% phenylephrine), aqueous tetracaine solution (SOCT 1%), microemulsion without tetracaine, microemulsion with tetracaine (MET 1%), gelled microemulsion without tetracaine, and gelled microemulsion with tetracaine (MEGT 1%). Each animal received a topical application of the formulation in the right nostril, followed by a subcutaneous injection of 2% formalin. The formulations exhibited nanometric particle sizes (58.2–161.7 nm), high polydispersity indices (0.50–0.56), and distinct zeta potential values (–41.2 mV for MET and +19.7 mV for MEGT). MEGT showed higher firmness, consistency, and mucoadhesive properties compared to MET. In the release assays, both MET and MEGT provided sustained tetracaine release for up to 6 hours (30.74% and 28.52%, respectively). The tetracaine-containing formulations significantly reduced nociceptive behavior, maintaining low and stable rubbing times, with efficacy comparable to that of the tetracaine + phenylephrine eye drops (p > 0.05). It was possible to develop and characterize nanostructured tetracaine formulations with suitable physicochemical properties, sustained drug release, and effective antinociceptive activity. Both MET and MEGT proved to be promising alternatives to conventional eye drop formulations.
- 17 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDevelopment and in Vivo Evaluation of Nanostructured Formulations for Topical Anesthesia in an Orofacial Pain Model
To develop and characterize nanostructured formulations of tetracaine and to evaluate their antinociceptive activity in an in vivo model of formalin-induced orofacial pain. Microemulsions of tetracaine (MET) and its gelled version containing 4% chitosan (MEGT) were obtained. The formulations were characterized for particle size, polydispersity index (PDI), zeta potential (ZP), mucoadhesiveness, and in vitro release. In the in vivo study, forty-two female Wistar rats were allocated into seven groups (n = 6): control, eye drops (1% tetracaine + 0.1% phenylephrine), aqueous tetracaine solution (SOCT 1%), microemulsion without tetracaine, microemulsion with tetracaine (MET 1%), gelled microemulsion without tetracaine, and gelled microemulsion with tetracaine (MEGT 1%). Each animal received a topical application of the formulation in the right nostril, followed by a subcutaneous injection of 2% formalin. The formulations exhibited nanometric particle sizes (58.2–161.7 nm), high polydispersity indices (0.50–0.56), and distinct zeta potential values (–41.2 mV for MET and +19.7 mV for MEGT). MEGT showed higher firmness, consistency, and mucoadhesive properties compared to MET. In the release assays, both MET and MEGT provided sustained tetracaine release for up to 6 hours (30.74% and 28.52%, respectively). The tetracaine-containing formulations significantly reduced nociceptive behavior, maintaining low and stable rubbing times, with efficacy comparable to that of the tetracaine + phenylephrine eye drops (p > 0.05). It was possible to develop and characterize nanostructured tetracaine formulations with suitable physicochemical properties, sustained drug release, and effective antinociceptive activity. Both MET and MEGT proved to be promising alternatives to conventional eye drop formulations.
- 23 January 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (2) , 83
Correction: Amphotericin B-Loaded Bigel: Characterization and in vivo Antileishmanial Evaluation in BALB/c Mice Infected with Leishmania amazonensis
- 23 January 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (2) , 83
Correction: Amphotericin B-Loaded Bigel: Characterization and in vivo Antileishmanial Evaluation in BALB/c Mice Infected with Leishmania amazonensis
- 8 January 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (1) , 65
Amphotericin B-Loaded Bigel: Characterization and in vivo Antileishmanial Evaluation in BALB/c Mice Infected with Leishmania amazonensis
American Tegumentary Leishmaniasis (ATL) is a zoonotic disease characterized by polymorphic cutaneous and mucosal manifestations, caused by protozoa of the
- 8 January 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (1) , 65
Amphotericin B-Loaded Bigel: Characterization and in vivo Antileishmanial Evaluation in BALB/c Mice Infected with Leishmania amazonensis
American Tegumentary Leishmaniasis (ATL) is a zoonotic disease characterized by polymorphic cutaneous and mucosal manifestations, caused by protozoa of the